Sakamuri D, et al. Mol. Cancer Ther. (2018) cited as Ref 635 in DOI: 10.1038/s41392-020-0110-5 (Q9898)
Jump to navigation
Jump to search
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Sakamuri D, et al. Mol. Cancer Ther. (2018) cited as Ref 635 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Sakamuri D
0 references
2018
0 references
Mol. Cancer Ther.
0 references
17
0 references
Phase I dose-escalation study of anti-CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers (English)
0 references
671-676
0 references
